Clinical Trial Update: Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating anlotinib plus sintilimab as first-line treatment for advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Colorectal Cancer, Immunotherapy | Phase 2 | Status: COMPLETED